Wenqi Zhao

Aug 19, 2024 | biorxiv.org | Suowen Xu |Zhenghong Liu |Tian Tian |Wenqi Zhao

AbstractObesity is a debilitating disease with increasing worldwide prevalence. Despite its high prevalence, specific pharmacologic intervention for obesity is challenging. Here, we report that halofuginone, an FDA-approved anti-scleroderma and anti-protozoal drug, is a promising anti-obesity agent in rodent models.

Jan 24, 2024 | dx.doi.org | Hao Chen |Wenqi Zhao |Haoyu Feng

Download Hi-Res ImageDownload to MS-PowerPointCite This:Ind. Eng. Chem. Res. 2024, XXXX, XXX This article has not yet been cited by other publications.